Proton Pump Inhibitor Use and Incident Epilepsy in the UK Biobank: Evidence From Pharmacovigilance and Multi‐Omics Analyses
CNS Neuroscience & Therapeutics · 2026-11 · 32 (11)
DOI: 10.1002/cns.71223 ↗Kurz gefasst
Fachartikel in der Zeitschrift CNS Neuroscience & Therapeutics, online erschienen am 04.11.2026. Verfasst von Minghao Li und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang Province, People's Republic of China. Hauptthemen laut MEDLINE: Proton Pump Inhibitors, Epilepsy, Pharmacovigilance, Biological Specimen Banks. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Aims
Proton pump inhibitors (PPIs) are widely used, but their association with incident epilepsy remains uncertain. We examined this association in the UK Biobank and integrated evidence from pharmacovigilance and multi‐omics.
Methods
We included 492,858 UK Biobank participants without epilepsy at baseline. Cox models, age‐ and sex‐stratified analyses, active‐comparator analyses against H2RA users, propensity score matching, competing‐risk models, and sensitivity analyses were performed. FAERS disproportionality, Olink proteomics, and NMR metabolomics provided supportive evidence.
Results
Baseline PPI use was associated with incident epilepsy after full adjustment (HR 1.43, 95% CI 1.29–1.59) and in the PPI‐H2RA propensity score‐matched analysis (HR 1.41, 95% CI 1.03–1.94). In the GP‐linked subset, requiring an ASM prescription within 365 days after diagnosis yielded HR 1.47 (95% CI 1.07–2.02). FAERS showed a PPI‐epilepsy reporting signal (ROR 1.70, 95% CI 1.61–1.79). Proteomic and metabolomic analyses identified immune‐inflammatory and metabolic associations.
Conclusion
Baseline PPI use was associated with incident epilepsy in the UK Biobank. Active‐comparator, outcome‐definition, and prescription‐supported analyses supported the primary association. Pharmacovigilance and molecular findings provided complementary evidence but did not establish causality.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang Province, People's Republic of China.
- Key Laboratory of Alzheimer's Disease of Zhejiang Province, Institute of Aging, Wenzhou Medical University, Wenzhou, Zhejiang Province, People's Republic of China.
- Key Laboratory of Novel Nuclide Technologies on Precision Diagnosis and Treatment & Clinical Transformation of Wenzhou City, Wenzhou, Zhejiang Province, People's Republic of China.
ORCID-Profile: Yuxi Zhang, Xinshi Wang
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Li, M., Li, Y., Zhang, Y., Saibou, B. S., Chen, Y., Xing, J., Jin, C., Xu, Y., Lin, J., & Wang, X. (2026). Proton Pump Inhibitor Use and Incident Epilepsy in the UK Biobank: Evidence From Pharmacovigilance and Multi‐Omics Analyses. CNS Neuroscience & Therapeutics, 32(11). https://doi.org/10.1002/cns.71223
Vancouver
Li M, Li Y, Zhang Y, Saibou BS, Chen Y, Xing J, et al. Proton Pump Inhibitor Use and Incident Epilepsy in the UK Biobank: Evidence From Pharmacovigilance and Multi‐Omics Analyses. CNS Neuroscience & Therapeutics. 2026;32(11). doi:10.1002/cns.71223
BibTeX
@article{Li2026,
author = {Li, Minghao and Li, Yiqian and Zhang, Yuxi and Saibou, Balkissou Seebo and Chen, Yifei and Xing, Jiayi and Jin, Chao and Xu, Yuchen and Lin, Jiahe and Wang, Xinshi},
title = {Proton Pump Inhibitor Use and Incident Epilepsy in the UK Biobank: Evidence From Pharmacovigilance and Multi‐Omics Analyses},
journal = {CNS Neuroscience & Therapeutics},
year = {2026},
volume = {32},
number = {11},
doi = {10.1002/cns.71223}
}
EUVIMED